This Article Full Text Full Text (PDF) All Versions of this Article: 40/3/820    most recent STROKEAHA.108.526376v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Zhu, Y. Articles by Sure, U. Search for Related Content PubMed PubMed Citation Articles by Zhu, Y. Articles by Sure, U. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Arteriovenous Malformations Related Collections Angiogenesis Cerebrovascular disease/stroke Acute Cerebral Hemorrhage Other Vascular biology

(Stroke. 2009;40:820.)
© 2009 American Heart Association, Inc.

Original Contributions

Involvement of PTEN Promoter Methylation in Cerebral Cavernous Malformations

Yuan Zhu, PhD; Andreas Wloch, MSc; Qun Wu, MSc; Christian Peters, MSc; Axel Pagenstecher, MD; Helmut Bertalanffy, MD Ulrich Sure, MD

From the Departments of Neurosurgery (Y.Z., A.W., Q.W., C.P., H.B., U.S.) and Neuropathology (A.P.), University of Marburg, Marburg, Germany.

Correspondence to Yuan Zhu, PhD, Department of Neurosurgery, University of Duisburg-Essen, Hufelandstr.55, 45122 Essen, Germany. E-mail yuan.zhu{at}uk-essen.de

Background and Purpose— Cerebral cavernous malformations (CCMs) are prevalent cerebral vascular lesions involving aberrant angiogenesis. However, the underlying mechanism is poorly understood. Phosphatase and tension homolog deleted on chromosome 10 (PTEN), a tumor suppressor, is frequently deficient in various pathologies due to mutation or epigenetic alterations. PTEN promoter hypermethylation is a major epigenetic silencing mechanism leading to activation of angiogenesis in tumors. The present study aimed to investigate whether PTEN promoter methylation was involved in CCMs.

Methods— PTEN promoter methylation was detected in surgical specimens of CCMs (n=69) by methylation-specific polymerase chain reaction. The methylation status was correlated to the clinical manifestations and to PTEN expression, which was analyzed by both Western blot and immunohistochemistry. To investigate the endothelial proliferation and the potential signaling pathways affected by PTEN methylation, proliferating cell nuclear antigen as well as phosphor-Akt and phosphor-Erk1,2 were detected by immunofluorescence and Western blot, respectively, in CCM specimens.

Results— Methylation-specific polymerase chain reaction revealed PTEN promoter methylation in 15.9% CCMs. Strikingly, 5 of 6 familial CCMs showed PTEN promoter methylation (83.3%), which was significantly higher than in sporadic cases (9.4%; P<0.001). In addition, PTEN promoter methylation appeared more frequently in multiple CCMs, including familial cases (46.7%), than that in single-lesioned CCMs (11.8%; P<0.05). Immunostaining and Western blot revealed a more significant PTEN downregulation in PTEN-methylated CCMs in comparison to PTEN-unmethylated CCMs. Reduced PTEN expression was inversely correlated to the expression of proliferating cell nuclear antigen and to the activation of Erk1,2, but not of Akt.

Conclusion— We reported here for the first time the involvement of PTEN promoter methylation in CCMs, particularly in familial CCMs, suggesting this epigenetic alteration as a potential pathomechanism of CCMs. The identification of Erk1,2 as triggered signaling in the lesions may be valuable for the development of effective therapy for this disease.

Key Words: cerebral cavernous malformation • endothelial proliferation • Erk1,2 activation • PTEN downregulation • PTEN promoter methylation